Insulet extends Amgen supply agreement through 2028, adds IP license

INSULET CORP

Amendment 21 extends term to December 31, 2028; parties to negotiate renewal by Jan 1, 2027.
Insulet and Amgen entered a Patent Assignment and License Agreement for IP rights.
New manufacturing site(s) added; Insulet responsible for equipment/labor to maintain quality.
Minimum purchase commitments revised but specific amounts redacted.
Payment terms amended; Safety Agreement terminated.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

INSULET CORP amended Amendment Number 21 with Amgen Inc. (effective 2023-06-01).

Action: amendment
Agreement: supply
Counterparty: Amgen Inc.
Effective: 2023-06-01

Exact text from the filing

On June 1, 2023, Insulet Corporation (the “ Company ”) and Amgen Inc. (“ Amgen ”) entered into Amendment Number 21 (“ Amendment 21 ”) to the Supply Agreement, dated as of November 21, 2013, between the Company and Amgen, as amended by Amendments 1-20, pursuant to which Insulet manufactures and sells to Amgen customized devices (the “ Original Agreement ”).

View on SEC.gov

Browse all material agreements →

INSULET CORP filing history →

Source: SEC EDGAR

accession 0001145197-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.